Wall St. Deal Watch: New Research on VSE, Alexion, LCNB Corp., Lime Energy and Mast Therapeutics

NEW YORK, January 2, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including VSE (NASDAQ: VSEC), Alexion (NASDAQ: ALXN), LCNB Corp. (NASDAQ: LCNB), Lime Energy (NASDAQ: LIME), and Mast Therapeutics (NYSEMKT: MSTX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

VSEC Research Report: ( http://get.analystsreview.com/pdf/?c=VSE&d=02-Jan-2015&s=VSEC ),

ALXN Research Report: ( http://get.analystsreview.com/pdf/?c=Alexion&d=02-Jan-2015&s=ALXN ),

LCNB Research Report: ( http://get.analystsreview.com/pdf/?c=LCNB%20Corp.&d=02-Jan-2015&s=LCNB ),

LIME Research Report: ( http://get.analystsreview.com/pdf/?c=Lime%20Energy&d=02-Jan-2015&s=LIME ),

MSTX Research Report: ( http://get.analystsreview.com/pdf/?c=Mast%20Therapeutics&d=02-Jan-2015&s=MSTX ).

============

--

Analyst Update: Acquisitions, Drug Applications, Fund Raising, and Upcoming Events

Reviewed by: Rohit Tuli, CFA®  

The US stock markets on Wednesday ended on a negative note amid the tumbling crude oil prices and light volume trade. In the last trading session of 2014, S&P 500 closed at 2,058.90, down 1.03%, NASDAQ Composite declined 0.87% to 4,736.05, and the Dow Jones Industrial Average edged 0.89% lower to finish the day at 17,823.07. However, the European stocks wrapped up the year on a positive note and were closed for trading on December 31, 2014. The Asian markets on the other hand ended the Wednesday's trading session on a mixed note as rising concerns over Greece's political crisis rattled the markets. Further, confirmation from HSBC that its index of China's manufacturing activity had contracted in December indicated a slowing Chinese economy despite government efforts to shore up development.

VSE Corporation (VSE) announced that it has agreed to acquire four business units from Killick Aerospace Group for an initial purchase price of $184 million in cash. VSE could also pay an additional price of up to $40 million if the acquired companies exceed certain thresholds of EBITDA during first two years after the closing of the acquisition. Find out more about the VSE's latest acquisitions in our detailed report.

Alexion Pharmaceuticals, Inc. (Alexion) announced completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP). Know more about latest development on Alexion's HPP drug in our research report.

LCNB Corp. has agreed to acquire BNB Bancorp, Inc., the holding company for Brookville National Bank of Brookville, Ohio ("Brookville National"), in a stock and cash transaction. The transaction, which is valued at approx. $12.6 million, is expected to close in second quarter of 2015. Know more about this acquisition and its impact on LCNB Corp.'s earnings going ahead in our research report.

Shares of Lime Energy Co. (Lime Energy) jumped nearly 17% on Wednesday, December 31, after the Company announced that it has raised $10 million from private equity firm Bison Capital to fund its growth. Andreas Hildebrand and Peter Macdonald of Bison Capital will join the Lime Energy's board. Find out how the Company plans to boost its growth with capital infusion from Bison Capital in our research report.

Shares of Mast Therapeutics Inc. (Mast Therapeutics) rallied 12% on Wednesday, December 31, as the Company announced plans to hold a conference call next week for providing updates on its pivotal phase 3 study, EPIC. Shares of Mast Therapeutics ended the session at $0.56, compared with previous day's closing price of $0.50. Know more about Mast Therapeutics' lead product candidate in our research report.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED